364 476
[8]
Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the Claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.[9]
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796–804.
[10]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
[11]
Prat A, Ellis MJ, Perou CM. Practical implications of gene-expres- sion-based assays for breast oncologists. Nat Rev Clin Oncol 2012;9:48–57.
[12]
von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemo- therapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366:299–309.
[13]
Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expres- sion. Cancer Cell 2004;5:489–500.
[14]
Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multi- forme. Proc Natl Acad Sci U S A 2005;102:5814–9.[15]
Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500–3.[16]
Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929–44.[17]
The Cancer Genome Atlas Research Network. Comprehensive mo- lecular characterization of urothelial bladder carcinoma. Nature 2014;507:315–22.[18]
Kim J, Akbani R, Creighton CJ, et al. Invasive bladder cancer: geno- mic insights and therapeutic promise. Clin Cancer Res 2015;21:4514–24.[19]
Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcrip- tional analysis of early-stage urothelial carcinoma. Cancer Cell 2016;30:27–42.
[20]
Ito N, Hiasa Y, Tamai A, Okajima E, Kitamura H. Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)ni- trosamine in rats. Gan 1969;60:401–10.
[21]
The Cancer Genome Atlas Network. Comprehensive genomic char- acterization of head and neck squamous cell carcinomas. Nature 2015;517:576–82.[22]
The Cancer Genome Atlas Research Network. Comprehensive ge- nomic characterization of squamous cell lung cancers. Nature 2012;489:519–25.[23]
Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 2016;48:600–6.[24]
Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 2015;5:704–12.[25]
Nordentoft I, Lamy P, Birkenkamp-Demtroder K, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep 2014;7:1649–63.
[26]
de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014;346:251–6.[27]
Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875–8.
[28]
Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expres- sion and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463–72.
[29]
Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706–9.
[30]
Spruck 3rd CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two mo- lecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784–8.
[31]
Lopez-Knowles E, Hernandez S, Kogevinas M, et al. The p53 path- way and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006;12:6029–36.[32]
Eriksson P, Aine M, Sjodahl G, Staaf J, Lindgren D, Hoglund M. Detailed analysis of focal chromosome arm 1q and 6p amplifica- tions in urothelial carcinoma reveals complex genomic events on 1q, and SOX4 as a possible auxiliary target on 6p. PLoS One 2013;8:e67222.[33]
Sauter G, Carroll P, Moch H, et al. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 1995;146:1131–9.
[34]
Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, et al. Recur- rent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013;45:1464–9.[35]
Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4:1140–53.
[36]
Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemother- apy in muscle-invasive bladder cancer. Eur Urol 2015;68:959–67.
[37]
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459–63.
[38]
Razzak M. Bladder cancer: STAG2 in the spotlight—have genomic studies identified a plausible biomarker? Nat Rev Urol 2013;10: 675.
[39]
Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating muta- tions of STAG2 in bladder cancer. Nat Genet 2013;45:1428–30.
[40]
Taylor CF, Platt FM, Hurst CD, Thygesen HH, KnowlesMA. Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet 2014;23: 1964–74.[41]
Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcrip- tase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360–6.
[42]
Borah S, Xi L, Zaug AJ, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015;347: 1006–10.
[43]
Huang FW, Hodis E, XuMJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957–9.
[44]
Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367–9.[45]
Kinde I, Munari E, Faraj SF, et al. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 2013;73:7162–7.
[46]
Nickerson ML, Dancik GM, Im KM, et al. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res 2014;20:4935–48.
[47]
Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and diseaseE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 5 4 – 3 6 5
364